Home › Obesità › North Carolina
Studi clinici su Obesità nello stato di North Carolina
60 studi su Obesità cercano partecipanti presso sedi nello stato di North Carolina.
Città nello stato di North Carolina
- Durham20 studi
- Havelock17 studi
- Charlotte16 studi
- Wilmington15 studi
- Greensboro12 studi
- Cary8 studi
- Statesville7 studi
- Winston-Salem7 studi
- Raleigh6 studi
- Greenville5 studi
- Fayetteville4 studi
- New Bern4 studi
- Concord3 studi
Testo ufficiale dello studio (inglese)
Tirzepatide in Obesity-Driven Endometrial Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
In reclutamentoFase 1 iniziale
Età 18 e oltre · Donne · Aggiornato il 2 ott 2026 · NCT07065552Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Medication Management /ID# 281965, Greensboro
- Monroe Biomedical Research /ID# 282009, Monroe
- Centricity Research - Morehead city /ID# 283264, Morehead City
- e altri 2
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07752979FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
- University of North Carolina at Chapel Hill, Chapel Hill
In reclutamento
Età da 18 a 75 · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06724406Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- TMA Headlands, Wilmington
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Medication Mgmnt, LLC_Grnsboro, Greensboro
- Accellacare of Raleigh, Raleigh
- Accellacare-Salisbury PMG Res, Salisbury
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- PharmQuest Life Sciences LLC, Greensboro
- Piedmont Healthcare/Research, Statesville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Medication Management, LLC, Greensboro
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Statesville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07776509Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UNC Children's Hospital, Chapel Hill
- Duke Children's Primary Care, Durham
- Lucas Research, Inc, Morehead City
In reclutamentoFase 3
Età da 6 a 17 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Coastal Research Institute - Fayetteville, Fayetteville
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937086AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- UNC Eastowne Medical Office, Chapel Hill
- PharmQuest Life Sciences LLC, Greensboro
- Accellacare and KDCILM, LLC, Wilmington
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT07339423A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- PharmQuest Life Sciences, LLC, Greensboro
- West Clinical Research, Morehead City
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- University of North Carolina Medical Center, Chapel Hill
- Medication Management, Greensboro
- Carteret Medical Group, Morehead City
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Monroe
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Novant Health Heart and Vascular Institute, Charlotte
- Velocity Clinical Research - Durham, Durham
- Moses H Cone Memorial Hospital, Greensboro
- e altri 7
In reclutamentoFase 3
Età da 45 a 99 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Monroe Biomedical Research, Monroe
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- e altri 1
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Charlotte
- AURORA-1 Clinical Site, Greenville
- AURORA-1 Clinical Site, Morehead City
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Charlotte
- AURORA-2 Clinical Site, Durham
- AURORA-2 Clinical Site, Greenville
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Asheville Cardiology Associates, Asheville
- Duke University Health System, Durham
- Ima Clinical Research - Lenoir, Lenoir
- e altri 2
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Centricity Research Morehead City Multispeciality, Morehead City
- Wake Forest University Health Sciences, Winston-Salem
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Lucas Research, Inc., Morehead City
- Shelby Clinical Research, Shelby
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Charlotte
- ACCOMPLISH-2 Research Site, Durham
- ACCOMPLISH-2 Research Site, Fayetteville
- e altri 2
In reclutamentoFase 3Volontari sani benvenuti
Età da 18 a 79 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- e altri 1
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Revival Research Institute, LLC, Cary
- Onsite Clinical Solutions - Huntersville, Huntersville
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- PharmQuest, Greensboro
- KDCILM, LLC & Accellacare US, Inc., Wilmington
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07745504Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Greensboro
- Kailera Clinical Site, Monroe
- Kailera Clinical Site, Morehead City
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Accellacare of Hickory, Hickory
- Carolina Research Center Inc, Shelby
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Morehead City
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- West Clinical Research, Morehead City
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Morehead City
- Kailera Clinical Site, Morrisville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Centricity Research Morehead City Specialty, Morehead City
- Accellacare of Raleigh, Raleigh
- Accellacare Research of Wilmington, Wilmington
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Statesville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT07784725Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors
- University of North Carolina at Chapel Hill, Chapel Hill
In reclutamento
Età da 18 a 39 · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06848491Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Levine Children's Hospital, Charlotte
In reclutamentoFase 2
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Peak Clinical Trials, Apex
- Hawthorne Health NC, Concord
- Duke University, Durham
- e altri 5
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07567001AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Piedmont Healthcare/Research, Statesville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Charlotte
- ACCOMPLISH-1 Research Site, Durham
- ACCOMPLISH-1 Research Site, Fayetteville
- e altri 3
In reclutamentoFase 3
Età da 18 a 79 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT07654361Mechanistic Study of Inspiratory Training in Childhood Asthma (MICA)
- Duke Health Center Creekstone, Durham
- Duke Healthy Lifestyles Clinic, Durham
In reclutamento
Età da 6 a 17 · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT05945355Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.